Skip to main content

Spero Therapeutics, Inc.

SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001701108

No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Spero Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of SPRO: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders8988−1
Shares17.5M18.4M+885.2K (+5.1%)
Value$244.2M$338.3M+$94.2M (+38.6%)

New holders (6)

Institutions that held Spero Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to SPRO in Q3 2021
InstitutionSharesValue% of portfolio
Williams Jones Wealth Management, LLC.105,500$1.94M0.03%
Brandywine Global Investment Management, LLC58,400$1.07M0.01%
Bourgeon Capital Management LLC41,746$769.0K0.16%
Campbell & CO Investment Adviser LLC23,900$440.0K0.14%
Sentinel Pension Advisors Inc20,200$372.0K0.13%
SG Americas Securities, LLC10,617$195.0K0.00%

Sold out (7)

Institutions that held Spero Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of SPRO in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Summit Global Investments13,100$183.0K
Citadel Advisors LLC11,812$165.0K
ProShare Advisors LLC11,608$162.0K
ExodusPoint Capital Management, LP10,933$153.0K
Simplex Trading, LLC507$7.00K
BDO Wealth Advisors, LLC75$1.00K
Rockefeller Capital Management L.P.10$0